Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group

被引：0
|
作者：
Ettrich, Thomas Jens
Berger, Andreas W.
Muche, Rainer
Lutz, Manfred P.
Prasnikar, Nicole
Uhl, Waldemar
Tannapfel, Andrea
Heinemann, Volker
Seufferlein, Thomas
机构：
[1] Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany
[2] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany
[3] Caritasklinikum, Saarbrucken, Germany
[4] Klinikum Ludwigsburg, Ludwigsburg, Germany
[5] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[6] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany
[7] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.tps497
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS497
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
    Von Hoff, Daniel D.
    Ervin, Thomas
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey
    Moore, Malcolm
    Seay, Thomas
    Tjulandin, Sergei A.
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Dowden, Scot
    Laheru, Daniel
    Bahary, Nathan
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Goldstein, David
    Van Cutsem, Eric
    Wei, Xinyu
    Iglesias, Jose
    Renschler, Markus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18): : 1691 - 1703
  • [22] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Heinrich, Stefan
    Pestalozzi, Bernhard
    Lesurtel, Mickael
    Berrevoet, Frederik
    Laurent, Stephanie
    Delpero, Jean-Robert
    Raoul, Jean-Luc
    Bachellier, Phillippe
    Dufour, Patrick
    Moehler, Markus
    Weber, Achim
    Lang, Hauke
    Rogiers, Xavier
    Clavien, Pierre-Alain
    BMC CANCER, 2011, 11
  • [23] Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
    Stefan Heinrich
    Bernhard Pestalozzi
    Mickael Lesurtel
    Frederik Berrevoet
    Stéphanie Laurent
    Jean-Robert Delpero
    Jean-Luc Raoul
    Phillippe Bachellier
    Patrick Dufour
    Markus Moehler
    Achim Weber
    Hauke Lang
    Xavier Rogiers
    Pierre-Alain Clavien
    BMC Cancer, 11
  • [24] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [25] Preoperative Gemcitabine Plus Nab-Paclitaxel is a Safe and Effective Neoadjuvant Chemotherapy for Resectable Pancreatic Adenocarcinoma
    Ielpo, Benedetto
    Vicente, Emilio
    Quijano, Yolanda
    Duran, Hipolito
    Diaz, Eduardo
    Fabra, Isabel
    Olivares, Sergio
    Caruso, Riccardo R. C.
    Ferri, Valentina V. F.
    Ferronetti, Antonio
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (04) : S144 - S144
  • [26] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Kimura, Ryuichiro
    Matsuda, Ryota
    Mori, Yasuhisa
    Nakata, Kohei
    Kakihara, Daisuke
    Fujimori, Nao
    Ohno, Takamasa
    Oda, Yoshinao
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1528 - 1534
  • [27] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Yoshihiro Miyasaka
    Takao Ohtsuka
    Ryuichiro Kimura
    Ryota Matsuda
    Yasuhisa Mori
    Kohei Nakata
    Daisuke Kakihara
    Nao Fujimori
    Takamasa Ohno
    Yoshinao Oda
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 1528 - 1534
  • [28] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [29] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
12345